Avenue Therapeutics enters stock contribution for Baergic Bio; Nasdaq non-compliance for audit committee

AVENUE THERAPEUTICS, INC.

Entered stock contribution agreement with parent Fortress to acquire 100% of Baergic Bio; conditions include $7.5M equity financing and repurchase of InvaGen shares.
Director Jay Kranzler determined not independent under Nasdaq rules; resigned from audit committee on May 13, 2022.
Company notified Nasdaq of non-compliance with audit committee composition rule; cure period available under Nasdaq Rule 5605(c)(4).
Faith L. Charles appointed to Board and audit committee to fill vacancies, effective May 16, 2022.

item 1.01 item 3.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Faith L. Charles

director

ATXI · AVENUE THERAPEUTICS, INC.

Effective: 2022-05-16
Filed: May 16, 2022, 7:59 PM ET

On May 16, 2022, the Board appointed Faith L. Charles as a director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Faith L. Charles was appointed as director at AVENUE THERAPEUTICS, INC..

Action: appointed
Role: director

Exact text from the filing

On May 16, 2022, the Board appointed Faith L. Charles as a director

View on SEC.gov

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-061412

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.